Behaviour Change for Cancer Survivors Trial
Launched by UNIVERSITY OF TORONTO · Sep 30, 2024
Trial Information
Current as of August 21, 2025
Recruiting
Keywords
ClinConnect Summary
The Behaviour Change for Cancer Survivors Trial is a study designed to help cancer survivors become more active through exercise. It compares two different programs: one that combines a virtual exercise program with standard exercise advice, and another that adds motivational support to help participants stick with their exercise routines. The goal is to encourage cancer survivors to engage in moderate to vigorous physical activity for at least 90 minutes each week, following recommended guidelines. Participants will be followed up six months and one year after the program to see how well they maintain their activity levels.
To be eligible for this trial, participants need to be at least 18 years old, have a confirmed diagnosis of cancer (stages I to III), and be at least 12 weeks post-surgery or 6 weeks since completing radiation treatment. They should also be physically inactive, meaning they currently do less than 90 minutes of exercise each week, and have access to a device with internet for virtual meetings. This study is open to all genders, and participants should not have any serious medical conditions that would prevent them from exercising safely. If you're a cancer survivor looking to improve your physical activity in a supportive environment, this trial might be a great opportunity for you!
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • ≥18 years of age
- • Confirmed diagnosis of cancer of any type (Stages I to III; localized)
- • Have completed primary cancer treatment within 5 years
- • At least 12 weeks after surgery completion
- • At least 6 weeks after radiation treatment
- • Proficient in English
- • Physically inactive (self-report less than 90 min of MVPA/week )
- • Ambulate in daily life with minimal gait aid use
- • Access to a smartphone/tablet/computer with webcam for videoconferencing and a Bluetooth connection
- • Access to the internet
- • No cardiac contraindications (e.g., unstable angina, heart failure, coronary artery disease, diagnosed abnormality of heart rhythm)
- Exclusion Criteria:
- • A medical condition that prohibits PA (e.g., joint restriction or weight bearing precautions)
- • Uncontrolled comorbidities or cardiovascular contraindications that would increase risk associated with supervised and unsupervised exercise (e.g., cardiac contraindications, severe arthritis, recent fall within the last 6-12 months)
- • Presence of advanced cancer (i.e., Stage IV; metastatic)
- • Do not intend to live in Canada for the next 18 months
About University Of Toronto
The University of Toronto, a prestigious research institution, serves as a leading sponsor of clinical trials dedicated to advancing medical knowledge and improving patient care. With a commitment to innovation and excellence, the university fosters a collaborative environment that brings together multidisciplinary teams of experts in medicine, pharmacology, and public health. Through rigorous research methodologies and ethical standards, the University of Toronto aims to explore new therapies, assess treatment efficacy, and address critical health challenges, ultimately contributing to the global body of scientific knowledge and enhancing healthcare outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Toronto, Ontario, Canada
Patients applied
Trial Officials
Linda Trinh, PhD
Principal Investigator
University of Toronto
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported